Clinical Trial Update: Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy update of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients aged 2 years and older; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Trikafta (elexacaftor/tezacaftor/ivacaftor) (elexacaftor/tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED